RxDoctor Payments Data

David Denman, MD

Family Medicine · Ringgold, GANPI 1942287453

Payments from drug & device makers

$14,323in general payments, 2019–2025

Across 772 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Amgen$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$854
  • Lilly USA, LLC$660
  • plus $7K from 54 others

What the payments were for

  • Travel & lodging$5494%
  • Food & beverage$13,72696%
  • Education$340%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)115$2,135
Pfizer92$1,184
Novo Nordisk65$1,174
Amgen(2 entities)69$1,001
Biohaven Pharmaceutical Holding Company Ltd.11$854
Lilly USA, LLC34$660
GSK34$522
Sanofi-aventis U.S. LLC31$515
Boehringer Ingelheim30$509
Regeneron Healthcare Solutions, Inc.4$483
Abbott23$394
AstraZeneca26$377
Amarin Pharma, Inc.20$347
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$333
Sumitomo Pharma America, Inc.9$271
Biohaven Pharmaceuticals, Inc.15$253
Dexcom, Inc.9$219
Astellas Pharma US Inc13$219
Merck14$197
Takeda Pharmaceuticals U.S.A., Inc.10$197
Xeris Pharmaceuticals, Inc.10$184
E.r. Squibb & Sons, L.L.C.11$180
Kowa Pharmaceuticals America, Inc.3$155
Novartis9$155
Esperion Therapeutics, Inc.9$146
Bayer7$138
Mylan Specialty L.p.7$122
Supernus Pharmaceuticals, Inc.9$120
Incyte Corporation1$90
Arbor Pharmaceuticals, Inc.6$88
Johnson & Johnson5$83
Heartflow, Inc.1$78
UCB, Inc.1$70
Paratek Pharmaceuticals, Inc.4$67
Teva Pharmaceuticals USA, Inc.4$61
Medtronic3$57
Axsome Therapeutics, Inc.2$56
Lundbeck LLC2$53
Upsher-smith Laboratories LLC2$45
Sunovion Pharmaceuticals Inc.4$45
Radius Health, Inc.2$41
Nevro Corp.2$36
Daiichi Sankyo Inc.2$33
Boston Scientific2$32
Phathom Pharmaceuticals, Inc.2$31
Inspire Medical Systems, Inc.2$29
Otsuka America Pharmaceutical, Inc.1$25
Jazz Pharmaceuticals Inc.1$24
Corcept Therapeutics1$24
Impel Pharmaceuticals Inc.1$22
Azurity Pharmaceuticals, Inc.1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Gilead1$17
Shire North American Group Inc1$16
Evoke Pharma, Inc.1$16
Averitas Pharma Inc.1$16
Shield Therapeutics Inc1$15
Exact Sciences1$14
Genentech USA, Inc.1$14
Optos, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,323 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$219,622
Medicare patients
521
Services billed
3,440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide386$513,129
OzempicSemaglutide188$249,044
EliquisApixaban232$244,144
Soliqua 100-33Insulin Glargine/Lixisenatide170$172,740
Tresiba Flextouch U-200Insulin Degludec134$150,660
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$127,342
JardianceEmpagliflozin89$118,588
Fasenra PenBenralizumab18$113,375
RybelsusSemaglutide60$106,191
GlyxambiEmpagliflozin/Linagliptin77$103,085
EnbrelEtanercept12$101,171
Humira PenAdalimumab14$97,401
XareltoRivaroxaban85$97,269
FarxigaDapagliflozin Propanediol76$79,811
EntrestoSacubitril/Valsartan66$68,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$660$577,858429 claims
Novo NordiskOzempic, Rybelsus$1,174$355,236248 claims
PfizerEliquis, Nurtec Odt$1,184$299,982269 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Stiolto Respimat$509$276,364226 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$515$172,740170 claims
GSKTrelegy Ellipta, Breo Ellipta$522$139,729167 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$377$123,415152 claims
AmgenEnbrel$1,001$101,17112 claims
Johnson & JohnsonXarelto$83$97,26985 claims
NovartisEntresto$155$68,24166 claims
AbbVieLinzess, Ubrelvy$2,135$48,08346 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$333$37,64412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Ringgold

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →